CL2009000022A1 - Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante. - Google Patents
Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante.Info
- Publication number
- CL2009000022A1 CL2009000022A1 CL2009000022A CL2009000022A CL2009000022A1 CL 2009000022 A1 CL2009000022 A1 CL 2009000022A1 CL 2009000022 A CL2009000022 A CL 2009000022A CL 2009000022 A CL2009000022 A CL 2009000022A CL 2009000022 A1 CL2009000022 A1 CL 2009000022A1
- Authority
- CL
- Chile
- Prior art keywords
- von willebrand
- factor
- willebrand factor
- procedure
- human
- Prior art date
Links
- 108010047303 von Willebrand Factor Proteins 0.000 title abstract 3
- 229940003169 factor viii / von willebrand factor Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000012141 concentrate Substances 0.000 title 1
- 102100036537 von Willebrand factor Human genes 0.000 title 1
- 229960001134 von willebrand factor Drugs 0.000 title 1
- 229960000301 factor viii Drugs 0.000 abstract 2
- 238000001728 nano-filtration Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0017—Filtration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
EL PROCEDIMIENTO SE CARACTERIZA POR LA PREPARACIÓN DE UNA SOLUCIÓN DE FACTOR VON WILLEBRAND O DE COMPLEJO DE FACTOR VIII/ FACTOR VON WILLEBRAND QUE CONTIENE FVW A UNA CONCENTRACIÓN DE HASTA 12 UI FVWRC0/M1 Y UNA PROPORCIÓN ENTRE FACTOR VON WILLEBRAND/FACTOR VIII SUPERIOR O IGUAL A 0,4; Y PROCEDER A CONTINUACIÓN A LA NANOFILTRACIÓN DE LA SOLUCIÓN PREPARADA EN A) MEDIANTE UN FILTRO DE TAMAFIO DE PORO MENOR DE 35 NANÓMETROS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200800021A ES2298096B1 (es) | 2008-01-08 | 2008-01-08 | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos. |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009000022A1 true CL2009000022A1 (es) | 2009-11-20 |
Family
ID=39316136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009000022A CL2009000022A1 (es) | 2008-01-08 | 2009-01-07 | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante. |
Country Status (17)
Country | Link |
---|---|
US (2) | US8354505B2 (es) |
EP (1) | EP2078730B9 (es) |
JP (1) | JP4976366B2 (es) |
CN (1) | CN101480490B (es) |
AR (1) | AR072441A1 (es) |
AT (1) | ATE509031T1 (es) |
AU (1) | AU2008255137C1 (es) |
BR (1) | BRPI0900057B8 (es) |
CA (1) | CA2645701C (es) |
CL (1) | CL2009000022A1 (es) |
ES (2) | ES2298096B1 (es) |
HK (1) | HK1129075A1 (es) |
MX (1) | MX2008015892A (es) |
NZ (1) | NZ573400A (es) |
PL (1) | PL2078730T3 (es) |
PT (1) | PT2078730E (es) |
RU (1) | RU2417096C2 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2861395B1 (fr) * | 2003-10-23 | 2006-02-17 | Lab Francais Du Fractionnement | Facteur viii viralement securise a faible teneur en multimeres superieurs |
US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
JP5784907B2 (ja) * | 2007-12-28 | 2015-09-24 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 組換え型vwf製剤 |
TWI593421B (zh) | 2008-10-21 | 2017-08-01 | 巴克斯歐塔公司 | 凍乾的重組vwf調配物 |
KR101969515B1 (ko) * | 2011-06-10 | 2019-04-16 | 박스알타 인코퍼레이티드 | 재조합 vwf의 투여에 의한 응고 질환의 치료 |
WO2012176876A1 (ja) * | 2011-06-24 | 2012-12-27 | 旭化成メディカル株式会社 | 蛋白製剤の製造方法 |
US11370827B2 (en) * | 2012-01-12 | 2022-06-28 | Bioverativ Therapeutics Inc. | Chimeric factor VIII polypeptides and uses thereof |
US20150080309A1 (en) | 2012-04-24 | 2015-03-19 | Nova Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
CN105705516B (zh) * | 2013-11-08 | 2019-11-01 | 杰特有限公司 | 浓缩von Willebrand因子或其络合物的方法 |
DK3152230T3 (da) * | 2014-06-06 | 2019-11-11 | Octapharma Ag | Præparat omfattende faktor viii og von willebrand-faktor-peptider |
CN104804078B (zh) * | 2015-05-05 | 2019-01-04 | 广东卫伦生物制药有限公司 | 人体血清凝血因子ⅷ中的病毒过滤方法 |
JP2020531516A (ja) * | 2017-08-23 | 2020-11-05 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | フォン・ウィルブランド因子のウイルスろ過の方法 |
AU2022326188A1 (en) | 2021-08-11 | 2024-02-22 | Grifols Worldwide Operations Limited | Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5110907A (en) * | 1989-08-01 | 1992-05-05 | Alpha Therapeutic Corporation | Factor viii complex purification using heparin affinity chromatography |
US5288853A (en) * | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
EP0860444A1 (en) * | 1997-02-24 | 1998-08-26 | Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) | Method for removing viruses from a protein solution |
AT406373B (de) | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
AT405485B (de) * | 1997-05-28 | 1999-08-25 | Immuno Ag | Eine das vwf-propeptid enthaltende pharmazeutische präparation |
FR2772381B1 (fr) * | 1997-12-15 | 2001-06-08 | Lab Francais Du Fractionnement | Procede de preparation par filtration d'une solution de facteur viii securisee viralement |
FR2861395B1 (fr) * | 2003-10-23 | 2006-02-17 | Lab Francais Du Fractionnement | Facteur viii viralement securise a faible teneur en multimeres superieurs |
FR2874216B1 (fr) * | 2004-08-16 | 2006-11-03 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu |
-
2008
- 2008-01-08 ES ES200800021A patent/ES2298096B1/es active Active
- 2008-11-28 EP EP08380326A patent/EP2078730B9/en not_active Revoked
- 2008-11-28 PT PT08380326T patent/PT2078730E/pt unknown
- 2008-11-28 AT AT08380326T patent/ATE509031T1/de active
- 2008-11-28 PL PL08380326T patent/PL2078730T3/pl unknown
- 2008-11-28 ES ES08380326T patent/ES2363827T3/es active Active
- 2008-12-03 CA CA2645701A patent/CA2645701C/en active Active
- 2008-12-03 NZ NZ573400A patent/NZ573400A/en not_active IP Right Cessation
- 2008-12-04 AU AU2008255137A patent/AU2008255137C1/en active Active
- 2008-12-09 CN CN2008101840044A patent/CN101480490B/zh active Active
- 2008-12-11 MX MX2008015892A patent/MX2008015892A/es active IP Right Grant
- 2008-12-24 JP JP2008328536A patent/JP4976366B2/ja active Active
- 2008-12-26 RU RU2008151957/15A patent/RU2417096C2/ru not_active IP Right Cessation
-
2009
- 2009-01-05 AR ARP090100004A patent/AR072441A1/es active IP Right Grant
- 2009-01-06 BR BRPI0900057A patent/BRPI0900057B8/pt active IP Right Grant
- 2009-01-07 US US12/349,604 patent/US8354505B2/en active Active
- 2009-01-07 CL CL2009000022A patent/CL2009000022A1/es unknown
- 2009-10-05 HK HK09109192.8A patent/HK1129075A1/xx not_active IP Right Cessation
-
2011
- 2011-06-20 US US13/164,117 patent/US20110275570A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP4976366B2 (ja) | 2012-07-18 |
HK1129075A1 (en) | 2009-11-20 |
US20110275570A1 (en) | 2011-11-10 |
NZ573400A (en) | 2010-02-26 |
EP2078730A1 (en) | 2009-07-15 |
ES2298096A1 (es) | 2008-05-01 |
BRPI0900057A2 (pt) | 2009-09-22 |
ES2298096B1 (es) | 2009-01-01 |
AU2008255137B2 (en) | 2011-04-07 |
EP2078730B9 (en) | 2011-12-21 |
AU2008255137C1 (en) | 2015-08-27 |
RU2008151957A (ru) | 2010-07-10 |
BRPI0900057B1 (pt) | 2021-03-23 |
CA2645701A1 (en) | 2009-07-08 |
RU2417096C2 (ru) | 2011-04-27 |
PL2078730T3 (pl) | 2011-10-31 |
JP2009161528A (ja) | 2009-07-23 |
CA2645701C (en) | 2013-09-17 |
EP2078730B1 (en) | 2011-05-11 |
MX2008015892A (es) | 2009-07-07 |
PT2078730E (pt) | 2011-07-14 |
AR072441A1 (es) | 2010-09-01 |
ATE509031T1 (de) | 2011-05-15 |
CN101480490A (zh) | 2009-07-15 |
CN101480490B (zh) | 2013-05-29 |
AU2008255137A1 (en) | 2009-07-23 |
ES2363827T3 (es) | 2011-08-17 |
US20090176709A1 (en) | 2009-07-09 |
US8354505B2 (en) | 2013-01-15 |
BRPI0900057B8 (pt) | 2021-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000022A1 (es) | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand de origen humano o recombinante. | |
CL2015003117A1 (es) | Modificaciones en la estructura cristalina | |
PE20160781A1 (es) | Formulaciones de insulina de accion prolongada | |
CL2011000901A1 (es) | Compuestos nitrogenados; composicion farmaceutica que comprende a dichos compuestos; su uso para la modulacion del flujo de cromoforos en un ciclo retinoide para tratar la degeneracion macular asociada con la edad, la distrofia macular de stargardt, desprendimiento de retina, retinopatia hemorragica, retinitis pigmentosa, neuropatia optica,uveitis. | |
ECSP10010370A (es) | Preparacion de solucion que contiene anticuerpos en una alta concentracion | |
CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
AR063892A1 (es) | Particulas de suministro que contienen agentes beneficos | |
PE20140190A1 (es) | Moduladores de proteinas notum y metodos de uso | |
ES2687651T3 (es) | Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos | |
MX362103B (es) | Composiciones para el cuidado oral para su uso con un dispositivo oral con luz. | |
EA201491934A1 (ru) | Аналоги глюкагоноподобного пептида-2 (glp-2) | |
NI201200013A (es) | Composición de insulina de acción prolongada | |
CL2011003091A1 (es) | Composicion que comprende conjugado covalente entre hemoglobina funcional y nativa y al menos una molecula de polietilenglicol; metodo para preparar composicion; uso de dicha composicion para producir medicina de transfusion. | |
CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
EA201490559A1 (ru) | Композиция для лечения свища | |
AR065963A1 (es) | Solucion acuosa de peroxido de hidrogeno, proceso para su preparacion y su uso | |
CL2015003634A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
MX2015001348A (es) | Cocleatos hechos con fosfatidilserina de soja. | |
AR085169A1 (es) | Absorcion de oxigeno y dioxido de carbono en un contenedor de uso individual | |
MX2016002492A (es) | Composiciones bioactivas derivables de concentrados de plaquetas, y metodos para prepararlas y usarlas. | |
PE20120169A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
UA117480C2 (uk) | Лікування цукрового діабету за допомогою складу інсуліну тривалої дії | |
EA201190285A1 (ru) | Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия | |
CL2019003459A1 (es) | Métodos de cultivo celular. | |
AR067352A1 (es) | Preparado de fruta estable con elevada concentracion de goma de acacia |